tbuckley/cabot-search huggingface dataset:
AB0981 DYNAMICS OF PAIN ACCORDING TO THE VAS SCALE, FUNCTIONAL ACTIVITY ACCORDING TO THE WOMAC INDEX AND QUALITY OF LIFE ACCORDING TO THE EQ-5D QUESTIONNAIRE IN ELDERLY AND SENILE PATIENTS WITH KNEE JOINT OSTEOARTHRITIS AFTER COVID-19
Authors: M. Letaeva, M. Koroleva, O. Malyshenko, J. Averkieva, T. Raskina
Journal: Annals of the Rheumatic Diseases (2022)

Objectives To evaluate the dynamics of pain on the VAS scale, functional activity according to the WOMAC index and quality of life according to the EQ-5D questionnaire in elderly and senile patients with knee joint osteoarthritis (OA) after COVID-19. Methods A total of 32 elderly and senile male patients with an established diagnosis of knee joint OA (according to the criteria of ACR, 1986) of stage II–III according to Kellgren–Lawrence, with pain ≥40 mm on a visual analog scale (VAS), who needed to take nonsteroidal anti-inflammatory drugs (NSAIDs), were included in the study. The median age of the patients included in this study was 72.6 (66.0; 79.3) years. All patients have been ill with COVID-19 for the last 6 months. Pain dynamics was assessed on the VAS scale, functional activity - on the WOMAC index, quality of life - on the EQ-5D questionnaire. Results When analyzing the clinical picture, it was found that the majority of patients - 22 people (68.8%) - had moderate COVID–19, 4 people (12.5%) – in mild form, 6 patients (18.7%) - in severe. The average duration of hospitalization was 14.0 (9.0; 17.0) days. The majority of patients were discharged with recovery - 30 people (93.75%), 2 people died (6.25%). The most frequent manifestations of postcovid syndrome in elderly and senile patients with OA: weakness – in 18 (56.2%) patients, arthralgia – in 17 (53.1%) and memory loss – in 14 (43.8%). There was a significant increase in the pain index on the VAS scale and the total WOMAC index after COVID-19. Pain on the VAS scale before COVID-19 was 45.9 (34.8; 72.4), after the disease - 60.9 (51.4; 68.5) (p&lt;0.001); the total WOMAC index was 46.3 (38.5; 51.2) and 63.1 (48.9; 76.2), respectively (p=0.007). There were no differences in the need for NSAIDs before and after the disease. When filling out the EQ-5D questionnaire, all the interviewed patients indicated health problems to one degree or another. When calculating the quantitative index after COVID-19, there was a deterioration in the health index, but the changes were unreliable. The “health thermometer” also changed in a similar way. Conclusion COVID-19 in elderly and senile patients with OA occurred in a variant of moderate severity in 22 (68.8%), severe - in 6 (18.7%), mild - in 4 (12.5%). The most frequent manifestations of postcovid syndrome in elderly and senile patients with OA: weakness, arthralgia and memory loss. Negative dynamics of indicators of functional activity according to the WOMAC index and pain on the scale VAS after COVID-19 was registered. Disclosure of Interests None declared
A shared disease-associated oligodendrocyte signature among multiple CNS pathologies
Authors: Mor Kenigsbuch, Pierre Bost, Shahar Halevi, Yuzhou Chang, Shuo Chen, Qin Ma, Renana Hajbi, Benno Schwikowski, Bernd Bodenmiller, Hongjun Fu, Michal Schwartz, Ido Amit
Journal: Nature Neuroscience (2022)
AB0805 Levels of Natural Killer Cells in patients with Ankylosing Spondylitis: A meta-analysis
Authors: H. Zhou, L. Xie, Q. Y. Su, G. M. Xia, J. Wang, S. X. Zhang, C. Wang
Journal: Annals of the Rheumatic Diseases (2022)

Background Ankylosing Spondylitis(AS) is a complex chronic inflammatory autoimmune disease that mainly affects the spine. Natural Killer (NK) cells are classified among the recently discovered innate lymphoid cell subsets and have capacity to influence both innate and adaptive immune responses. However, the status of NK cells remains debated in AS. Objectives This study aims to clarify the level of peripheral NK cells in AS patient. Methods We used CNKI, CBM, Wanfang data and Chinese science, scientific and technological journal data, PubMed, Embase, Web of science, Cochrane library and Medline to collect relevant literature data, and sorted out the proportion of NK cells in AS patients. Random effects were selected to assess pooled data, inconsistency was assessed using I-squared index (I 2 ), and Egger’s test was used to assess potential publication bias (STATA v.12.0). Results A total of 11 case-control studies involving 561 AS patients and 592 healthy controls (HC) were included in this study. AS patients had a significantly lower proportion of CD16 + CD19 + NK cells compared with HCs［SMD=-0.41, 95%CI (-0.71,-0.11), P&lt;0.05,］(Figure 1), with no publication bias according to Egg’s test[t=0.50, P=0.63]. Conclusion The proportion of of CD16 + CD19 + NK cells in AS patients was significantly reduced, suggesting disturbance of NK closely involved in the pathogenesis of AS. Table 1. Summary of study characteristics of included records. Author Publish year EI a Q b Case numbers NK cell’s definition Data Type Mean % of NK cell(mean(or median)±SD) AS HC Qian Liu 2021 4 7 121 120 CD16+CD56+ Original AS:17.6HC:138.9 Yu Zhang 2019 4 6 39 41 CD16+CD56+ Original AS:22.78HC:61.12 Wei Hu 2019 4 6 60 40 CD16+CD56+ Original AS:13.3HC:48.1 Liyuan Zhu 2016 4 7 30 30 CD16+CD56+ Original AS:16.23HC:44.58 Hua Liu 2012 4 5 60 30 CD16+CD56+ Original AS:29.99HC:49.5 Yongfang Wang 2012 4 6 60 44 CD16+CD56+ Original AS:14.04HC:60.12 Yuehu Hua 2012 4 7 36 32 CD16+CD56+ Original AS:31.1HC:59.8 Li Ma 2011 4 6 43 20 CD16+CD56+ Original AS:24.98HC:38.15 Xuehua Ma 2011 4 6 36 32 CD16+CD56+ Original AS:31.1HC:59.8 Yong-Wook Park 2009 4 7 41 173 CD16+CD56+ Calculated AS:25.4HC:190.4 Li Ma 2004 4 7 35 30 CD16+CD56+ Original AS:33.48HC:52.37 Acknowledgements This work was supported by the National Natural Science Foundation of China (No. 82001740). Disclosure of Interests None declared
AB1527-HPR FUNCTIONAL SOMATIC SYNDROMES AND INSOMNIA IN PATIENTS WITH FIBROMYALGIA, RELATIONSHIP WITH THE INTENSITY OF THE PAIN SYNDROME
Authors: V. Bykov, V. Khomenko, L. Shvets, L. Perebetiuk, O. Ostapchuk, I. Shapoval, M. Stanislavchuk
Journal: Annals of the Rheumatic Diseases (2022)

Background Fibromyalgia (FM) is a chronic diffuse musculoskeletal pain manifested by numbers of functional somatic syndromes (1). The pathogenesis and pathophysiology of fibromyalgia includes changes of autonomic nervous system, which can be realized in the abnormal functioning of many organs and systems. Objectives Analyze the frequency and spectrum of functional somatic syndromes and insomnia in patients with fibromyalgia, relationship with the intensity of pain. Methods We examined 102 women with FM according criteria ACR (1990), mACR (2010) with mean age 41.7±9.4 years (M±σ), duration of the disease was 8.4 ± 6.28 years. The severity of pain, fatigue, sleep disorders was assessed with a visual analog scale (VAS). Results The severity of pain (VAS) in patients with FM ranged from 2.1 to 8.5 and averaged 5.1±1.5. The severity of fatigue was estimated at 6.5 ± 1.7, sleep disorders - 6.3 ± 2.7. In the examined group of patients with FM, in addition to typical clinical manifestations, significant numbers of functional disorders were diagnosed: insomnia - 86.3%, irritable bowel syndrome – 59,8%, postural tachycardia syndrome - 53.9%, hyperventilation syndrome - 52.9%, bladder pain syndrome – 50,0%. According to the intensity of pain, patients were divided into 3 groups. The 1th group included patients with pain less than 4 points (&lt;25th percentile, n = 21), the 2nd - with the pain severity 4-6 points (25-75th percentile, n = 58), the third group - patients with pain more than 6 points (&gt;75th percentile, n = 23). According to the study, the frequency of functional somatic syndromes was not related to the intensity of pain. There was a positive correlation between the severity of insomnia and the intensity of pain (r=0.36; p&lt;0.05). The same relationship was revealed between fatigue and pain (r=0.41; p&lt;0.05). Conclusion Patients with FM have a wide spectrum of functional somatic syndromes. The changes described were not related to the severity of the pain syndrome. The presence of correlations between the severity of insomnia and the intensity of pain requires further research to develop algorithms for comprehensive treatment of identified disorders. References [1]Donnachie, E., Schneider, A., &amp; Enck, P. (2020). Comorbidities of Patients with Functional Somatic Syndromes Before, During and After First Diagnosis: A Population-based Study using Bavarian Routine Data. Scientific reports , 10 (1), 9810. https://doi.org/10.1038/s41598-020-66685-4 Disclosure of Interests None declared
AB0249 EVALUATION OF BELIEFS AND FEARS DURING RHEUMATOID ARTHRITIS TOWARDS CONVENTIONAL BACKGROUND TREATMENTS: STUDY BY BMQ (BELIEF ABOUT MEDICATION QUESTIONNAIRE)
Authors: S. Abdellatif, H. Hachfi, M. Brahem, Y. Mohamed
Journal: Annals of the Rheumatic Diseases (2022)

Background Poor adherence is one of the main causes of therapeutic failure in chronic inflammatory rheumatism, particularly in rheumatoid arthritis (RA). Thus to improve regular intake especially of conventional background treatments (cs-DMARDs), it is important to assess patients’ beliefs and fears about their treatments. Objectives Evaluate the beliefs and fears of patients with Rheumatoid arthritis towards their conventional background treatments. Methods This is a cross-sectional study with RA follow-up patients meeting the ACR/EULAR criteria. Epidemiological, clinical and paraclinical data were collected. The evaluation of beliefs and fears towards csDMARDs was carried out by the BMQ score which has two five-item scales rated according to a 5-point Likert scale, ranging from 1 (not at all agree) to 5 (strongly agree). The scores of necessity, fear, overuse and nuisance were calculated. Patients were divided into 4 groups according to their beliefs of csDMARDs: accepting, ambivalent, indifferent and septic. Results The mean Disease Activity Score (DAS28crp) was 3.5 ±1.54, the mean value of Visual analogue scale of pain (VAS) was 40.5± 20.5, and the mean value of Health Assessment Questionnaire (HAQ) was 1.05± 0.85. All patients were treated with methotrexate and 12.5% with Salazopyrine in combination. The average need score was 20± 2.4, fear score was 16.45± 3, overuse score was 13.67± 2.25 and nuisance score was 10.8± 2.6. Patients’ beliefs about the need for their background treatments were more important than their concerns and fears about the potential consequences of these treatments (p=0.03). A higher necessity score was correlated with the number of painful joints (NAD) (p=0.02) and a higher DAS28 (p=0.05). Patients who were more afraid of their treatments had more joint deformities (p=0.03), higher HAQ functional index (0.007) and a higher VAS value (p=0.01). The belief profile study concluded that 60% of patients were ambivalent, 27.5% accepting, 10% indifferent and 2.5% were septic towards their background treatments. Conclusion Our study showed that during RA, knowledge of the profiles of our patients, their beliefs and fears about their treatments especially cs-DMARDs is essential, and could help us to adapt strategies for improving compliance. Disclosure of Interests None declared
AB1033 RADIOFREQUENCY ECHOGRAPHIC MULTI SPECTROMETRY (REMS) FOR THE ASSESSMENT OF FEMORAL BONE HEALTH IN A MALE POPULATION
Authors: F. A. Lombardi, P. Pisani, A. Natale, E. Casciaro, M. DI Paola, R. Franchini, M. Muratore, F. Conversano, S. Casciaro
Journal: Annals of the Rheumatic Diseases (2022)

Background Bone mass reaches the peak during the third decade of life. By this age, men reach an increased bone mass that starts declining in their fifties, however less rapidly than women after menopause. However, men and women lose bone mass at the same rate by age 65-70, becoming fragile and more likely to have fracture. Objectives This study aimed to evaluate the diagnostic accuracy in osteoporosis diagnosis of Radiofrequency Echographic Multi Spectrometry (REMS) technology applied on the proximal femur in an adult male population in comparison with the Dual-energy X-ray Absorptiometry (DXA). Methods A cohort of Caucasian males was enrolled in the study. Inclusion criteria were: age between 30 and 90 years, body mass index (BMI) less than 40 kg/m 2 , no significant walking impairments and proximal femur DXA medical prescription. All the enrolled patients underwent proximal femur scans with both DXA and REMS. The agreement between REMS and DXA-measured BMD was expressed by Pearson correlation coefficient and Bland-Altman method. The classification into patients “with osteoporosis” or “without osteoporosis” was carried out considering the conventional threshold of T-score (-2.5) for both techniques independently. The accuracy was evaluated by the assessment of sensitivity and specificity considering the DXA outcome as reference [1]. Results A total of 219 men were included in the analysis, with mean age of 55.5 (± 15.3) years. The Pearson correlation coefficient between REMS- and DXA-measured BMD values was r=0.94. At Bland-Altman analysis, Bias ± 1.96 Standard Deviation were -0.004 ± 0.04 g/cm 2 . The REMS capability to discriminate osteoporotic patients from non-osteoporotic ones was very high: a sensitivity of 90.0% and specificity of 91.8% was detected. Conclusion REMS, applied to the proximal femur site, is a reliable technology for the diagnosis of osteoporosis also in men, thus confirming the diagnostic performance already observed in studies carried out in female populations [1, 2]. References [1]Di Paola P et al. Osteoporos Int. 2019; 30(2):391-402. [2]Adami G et al. Bone 2020; 134:115297. Disclosure of Interests Fiorella Anna Lombardi: None declared, Paola Pisani: None declared, Alessandra Natale: None declared, Ernesto Casciaro Shareholder of: Ernesto Casciaro owns stocks of Echolight Spa, Marco Di Paola: None declared, Roberto Franchini: None declared, Maurizio Muratore: None declared, Francesco Conversano Shareholder of: Francesco Conversano owns stocks of Echolight Spa, Sergio Casciaro Shareholder of: Sergio Casciaro owns stocks of Echolight Spa
AB0606 Health-related quality of life in patients with rituximab-induced remission of ANCA-associated vasculitis: registry-based cohort studies
Authors: V. Babak, M. Suprun, T. Beketova
Journal: Annals of the Rheumatic Diseases (2022)

Background Survival rate in ANCA-associated vasculitis (AAV) has significantly improved due to anti-B cell therapy with rituximab (RTX). The main issue now appears to be the management of comorbidities and the improvement of quality of life. Objectives Based on a prospective analysis of the single centre registry of AAV patients (pts) treated with RTX, to study the impact of sustained remission on health-related quality of life using Short-Form 36 (SF-36). Methods Health-related quality of life was assessed in 70 AAV pts: 35 (50%) with granulomatosis with polyangiitis (GPA), 24 (34.3%) - microscopic polyangiitis (MPA) and 11 (15,7%) - eosinophilic granulomatosis with polyangiitis (EGPA). The mean age was 49,7 ± 15,7 years, 53% women. The median total dose of RTX was 4.3± 2,5 g. As a rule, a reduced dose of RTX 500 mg was used for repeated courses. Mean duration of RTX therapy 46.8 ± 29.4 months. Remission of AAV was defined as a Birmingham Vasculitis Activity Score = 0 regardless of prednisone treatment or dosage. All pts were in remission. Results In 70 patients the average indicators of physical functioning: MPA 62.5 (47.5, 78.8), GPA 75 (55, 92.5), EGPA 60 (45, 77.5); social functioning: MPA 25 (0, 56.3), GPA 50 (25, 100), EGPA 50 (12.5, 62.5), physical health component: MPA 41.6 (31.5, 44.8), GPA 43.7 (36.7, 52.5), EGPA 38.7 (33.8, 45). There were no significant differences between men and women within the GPA, MPA, and EGPA groups. There were also no differences between different age groups. When comparing the EGPA group with GPA or MPA, no significant differences were found. At the same time, in patients with MPA, the indicators of physical functioning (p=0.015, w= 3.92) and the physical component of health (p=0.012, w 4.026) were significantly lower than in patients with GPA. Conclusion RTX maintenance allows to achieve a good quality of life in AAV pts. SF-36 summary measures were significantly higher in GPA pts compared with MPA. Further research is required to analyze the effect of AAV phenotype and complications on health-related quality of life. References [1]V.N. Amirdzhanova, D.V. Goryachev, N.I. Korshunov, et al. Population indicators of the quality of life according to the SF-36 questionnaire (results of the multicenter study of the quality of life “MIRAGE”) SCIENTIFIC AND PRACTICAL RHEUMATOLOGY No. 1, 2008. https://doi.org/10.14412/1995-4484-2008-3 [2]Yun, JD., Ha, J., Kim, S. et al. Predictor of depressive disorders in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clin Rheumatol 38, 3485–3491 (2019). https://doi.org/10.1007/s10067-019-04657-4 Disclosure of Interests None declared
AB0910 EVALUATION OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH PSORIASIC ARTHRITIS UNDER TREATMENT WITH METHOTREXATE
Authors: L. Pérez Albaladejo, I. Añón Oñate, M. J. Perez Galan, C. Caro Hernandez
Journal: Annals of the Rheumatic Diseases (2022)

Background Nowadays, non-alcoholic fatty liver is the most common hepatic disease. In patients with psoriatic arthritis with metabolic syndrome or obesity, there is a state of inflammation that produces the existence of a replacement of normal hepatic tissue by connective tissue, creating a non-alcoholic fatty liver disease (NAFLD). Disease Modifying Anti- Rheumatic Drugs (DMARDs) are widely used in the treatment of psoriatic arthritis. Among these drugs, we find methotrexate, chosen as the primary treatment for such pathologies. This DMARD must be administrated cautiously in patients with risk of developing fatty liver since it is hepatotoxic and it might cause the development of a hepatic disease. Objectives Measure the risk of developing hepatic fibrosis in patients with psoriatic arthritis under methotrexate. Methods It is a study of retrospective cohorts to determine the existence of NAFLD in patients with psoriatic arthritis under methotrexate through fatty index biomarkers (FIB-4). 41 patients have been studied for more than a year. Demographical &amp; clinical variables have been collected (sex &amp; gender) and (BMI, tobacco, use of alcohol, dyslipidemia and AHT), scales of disease activity and the FIB-4 (transaminases, age, platelets). A baseline evaluation was made at 6 and 12 months with a 3 years extension of the treatment. Results A total of 41 patients (17 women &amp; 24 men), with an average age of 50.3 years (minimum 18 and maximum 80) and a BMI of 28.16 has been studied. 4.9% consumed alcohol habitually, 17.1% were smokers, 39% had hypertension, 41.5% had hypercholesterolaemia and 17.1% hypertriglyceridemia. Most patients had a moderate disease (DAPSA 20.9) at the beginning of treatment and kept a low activity in posterior months (DAPSA 6-8). The results of the Friedman’s test indicate that there are no significant statistic differences on the different measurements of FIB-4 (P=0.575). In the study can be seen an increasing evolution of the FIB-4 values through the first months that is later stabilized through time. When studying if the evolution of FIB-4 is related to the evolution of BMI, it can be observed that exists a significant statistic relation in the evolution of both measures but being such relation quite weak. The evolution of the classification of the patients’ FIB-4 at the beginning, at 6 months, at 1 year and at 3 years of treatment with methotrexate does not present significant statistic differences. Conclusion In patients with psoriatic arthritis, the treatment with methotrexate does not seem to increase the risk of developing a non alcoholic fatty liver disease. Graphics FIB-4 evolution Relation of the BMI and FIB-4 Disclosure of Interests None declared
AB1520 EFFECTIVE TREATMENT OF TOCILIZUMAB IN PATIENTS WITH REFRACTORY ADULT-ONSET STILL’S DISEASE
Authors: T. Cheng, Z. Chen, J. Tan, Y. Jiang, Z. Liao
Journal: Annals of the Rheumatic Diseases (2022)

Background Pro-inflammatory cytokines such as interleukin 6 (IL-6) are involved in the pathogenesis of adult-onset Still’s disease (AOSD). Anti-IL-6 agents such as tocilizumab have been tried to treat AOSD successfully. Objectives To access the efficacy of tocilizumab in the treatment of AOSD patient refractory to,or with initial treatment. Methods We reviewed three cases with refractory AOSD treated with tocilizumab. All patients fulfill the Cush criteria for AOSD. All patients performed blood culture, auto-antibodies test and bone marrow test to exclude infectious diseases, other rheumatic diseases and tumors. All patients received broad-spectrum antibiotics and had no response. All patients received glucocorticoid therapy and at least one kind of anti-cytokine therapies but didn’t have full response. Then the three patients received intravenous tocilizumab treatment of 8mg/kg every 2 weeks or 4 weeks. Results The first patient, a 21-year-old woman, performed positron emission tomography (PET-CT) and lymphoglandula pathology in addition to routine tests. She received high dose methylprednisolone (500mg per day for 3 days and followed by 80mg per day), gamma globulin injection (20g per day for 3 days) and baricitinib 4mg per day for 12 days, but had no response to the treatment. Then she received tocilizumab of 8mg/kg every 2 weeks and stopped baricitinib. And the symptoms and blood tests improved gradually, and the methylprednisolone dose reduced to 16mg per day at the last follow-up. The second patient is a 52-year-old man, and performed bone marrow cytology and PET-CT to excluded hematological diseases. He received methylprednisolone 80mg per day, adalimumab and tofacitinib treatment. But the patients still got recurrent fever, high ESR, CRP and serum ferritin. Then he stopped adalimumab and tofacitinib, and received tocilizumab of 8mg/kg every 2 weeks and reduced to 8mg/kg every 4 weeks because of economic factors. The patient did not develop fever and the inflammatory indexes such as ESR/CRP gradually decreased to normal range. And methylprednisolone dose reduced to 32mg nowadays. The third patient is a 30-year-old woman and has recurrent AOSD for 15 years. She had tried glucocorticoids, methotrexate, iguratimod, baritinib and entanercept successively. Yet she still had recurrent arthritis on hand and knee, and elevated ESR/CRP/serum ferritin. Additionally she suffered femoral head necrosis because of excessive doses of glucocorticoid. The patient received tocilizumab 8mg/kg every 4 weeks, then joint symptoms and inflammatory indicators improved significantly. The methylprednisolone dose was also successfully reduced to 4mg/d. The Figure 1 showed the main course of disease evolution. Figure 1. Conclusion Tocilizumab may be an effective candidate in refractory AOSD despite no response to other treatments. Disclosure of Interests None declared